Matching articles for "Cortiment"
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • July 10, 2023; (Issue 1680)
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and...
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and CD
have been updated in recent years
Ozanimod (Zeposia) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • September 20, 2021; (Issue 1633)
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative...
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative colitis. It
is the first S1P receptor modulator to be approved for
treatment of ulcerative colitis. Ozanimod was approved
in March 2020 for use in adults with relapsing forms of
multiple sclerosis.
In Brief: Extended-Release Budesonide (Ortikos) for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • November 2, 2020; (Issue 1610)
An oral extended-release formulation of the corticosteroid
budesonide (Ortikos – Ferring) is now available
for once-daily treatment of mild to moderate active
Crohn's disease of the ileum and/or ascending...
An oral extended-release formulation of the corticosteroid
budesonide (Ortikos – Ferring) is now available
for once-daily treatment of mild to moderate active
Crohn's disease of the ileum and/or ascending colon in
patients ≥8 years old and for maintenance of remission
for up to 3 months in adults. Ortikos is the second oral
formulation of budesonide to be approved for this
indication; Entocort EC, an ileal-release formulation,
was the first. A third oral formulation of budesonide
(Uceris) is approved for induction of remission in
patients with mild to moderate active ulcerative colitis.
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • July 2, 2018; (Issue 1550)
Management of both ulcerative colitis (UC) and Crohn's
disease (CD) is based on disease severity. Disease
location (proctitis, left-sided colitis, or extensive
colitis) also plays a role in drug selection....
Management of both ulcerative colitis (UC) and Crohn's
disease (CD) is based on disease severity. Disease
location (proctitis, left-sided colitis, or extensive
colitis) also plays a role in drug selection. Some
drugs for induction and maintenance of remission of
inflammatory bowel disease (IBD) are listed in Table 1.